Chugai Pharmaceutical Co Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
623 / 1328
Position in country
3556 / 4811
Return on Assets, %
17.7
-2.7
Net income margin, %
33.3
2.8
Debt to Equity, %
0.8
19.2
Intangible assets and goodwill, %
1
3.6
Revenue CAGR 3Y, %
12.1
8.5
Total Equity change 1Y, %
6
0
Revenue Y, % chg
-18
0.5
P/E
26.4
22.7
P/BV
5.3
1.5
P/S
7.9
2.3
EV/S
7.2
2.4
EV/EBITDA
18.1
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
156.9
51.3
Forward P/E
24.6
15.6
Dividend Yield, %
1.5
1.7
Forward Dividend Yield, %
3.5
0.2
Expected dividend per share
0.5
0
Payout Ratio, %
40.4
30.3
Competitors
Ranks
-
Daiichi Sankyo Co Ltd
00%
-
Ono Pharmaceutical Co Ltd
00%
-
Kyowa Kirin Co Ltd
00%
-
Shionogi & Co Ltd
00%
-
Taisho Pharmaceutical Holdings Co Ltd
00%
-
Chugai Pharmaceutical Co Ltd
00%
-
Takeda Pharmaceutical Co Ltd
00%
-
Eisai Co Ltd
00%
-
Otsuka Holdings Co Ltd
00%
-
Astellas Pharma Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Japan
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
57370.8
Ticker
CHGCY.PK
ISIN
US1712691039
IPO date
1956-03-03
Availability on Russian exchanges
No
Reporting for
2024-03-29
Date fact. publication of reports
2023-12-31
Company Description
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: